Skip to content
← Gastrointestinal Neuroendocrine Tumors

HEALTH PROFESSIONAL · SOURCE READING

Symptomatic Therapy

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

In addition to the use of long-acting depot formulations of somatostatin analogues to ameliorate neuroendocrine tumor symptoms, supportive care of patients includes:

Advising them to avoid factors that induce flushing or bronchospastic episodes, including:

Advising them to avoid factors that induce flushing or bronchospastic episodes, including:

Ingestion of alcohol, certain cheeses, capsaicin-containing foods, and nuts.

Advising them to avoid factors that induce flushing or bronchospastic episodes, including:

Stressful situations.

Advising them to avoid factors that induce flushing or bronchospastic episodes, including:

Some kinds of physical activity.

Diarrhea may be treated with conventional antidiarrheal agents such as loperamide or diphenoxylate; more pronounced diarrhea may be treated with the 5-HT receptor subtype 2 antagonist cyproheptadine, which is effective in as many as 50% of patients and may also help alleviate anorexia or cachexia in patients with a malignant carcinoid syndrome.[1]

Source links and citations

Histamine 1 receptor blockade with fexofenadine, loratadine, terfenadine, or diphenhydramine may help treat skin rashes, particularly in histamine-secreting gastric neuroendocrine tumors.

Bronchospasm can be managed with theophylline or beta-2 adrenergic receptor agonists such as albuterol.[1]

Source links and citations

Carcinoid crisis is manifested by profound flushing, extreme blood pressure fluctuations, bronchoconstriction, dysrhythmias, and confusion or stupor lasting hours or days and may be provoked by induction of anesthesia or an invasive radiologic procedure.[18,31] This potentially fatal condition can occur after manipulation of tumor masses (including bedside palpation), administration of chemotherapy, or hepatic arterial embolization.[32] In contrast with the treatment of other causes of acute hypotension, the use of calcium and catecholamines should be avoided in carcinoid crisis because these agents provoke the release of bioactive tumor mediators that may perpetuate or worsen the situation. Plasma infusion and octreotide are used for hemodynamic support. For the most part, the use of somatostatin analogues has replaced other pharmacological maneuvers in the treatment of crises, and their use has been associated with increased survival rates. Prophylactic use of subcutaneous octreotide or the administration of a depot somatostatin analogue in a timely fashion before any procedures are undertaken is mandatory to prevent the development of a crisis.[1]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice